Earnings call transcript: Genomma Lab tops Q3 2026 forecasts as Mexico recovers

Genomma Lab reported stronger-than-expected earnings for Q3 2026, surpassing Wall Street expectations. The Mexican consumer health company announced earnings per share of $0.51, outperforming the $0.46 forecast and revenue of $4.5 billion, slightly above the $4.43 billion estimate. Shares rose 1.32% to $14.57 in after-hours trading, remaining below its 52-week high of $19.48 but trading above $12.22.

Genomma Lab's Mexico-based operations displayed stronger growth, with sales returning to growth and market share recovering. The company faces pressure in the U.S., where sales fell 30% and sell-out declined 8.8% in local currency. Genomma Lab's isotonic beverage brand, Suerox, reported strong gains, driven by new product launches and manufacturing changes.

Management acknowledged the need to accept lower margins in the near term for stronger growth and market share. The company's Q3 performance reflects a strategic move to boost promotions and commercial activity, with promising results in Mexico and Latin America. Sales in the U.S. remained weak due to distribution gaps and a soft Hispanic retail market.

Net sales increased 1.3% to MXN 4,497 million, with net income rising 18.6% to MXN 550 million. EBITDA was MXN 945 million, with a 21% margin, down 271 basis points from the previous year. Operating cash flow rose 12.5% year over year, and free cash flow increased 52%, reflecting strong cash generation relative to market value.

Genomma Lab's earnings per share exceeded expectations by 10.87%, while revenue surpassed forecasts by 1.58%. The mixed results indicate progress in some markets and continuing challenges in others, including margin pressure and uneven demand. The stock currently trades 25.2% above the 52-week low and 25.2% below the 52-week high, reflecting a business that is growing but still facing significant obstacles.